YOLFTbeta
Intensity Therapeutics, Inc. Common stock

Intensity Therapeutics, Inc. Common stock

INTS · NASDAQ · Healthcare / Biotechnology

3.08USD-0.02 (-0.65%)

Price History

Full chart

Market Stats

Previous Close3.10
Open3.06
Day Range2.92 – 3.09
52-Week Range3.51 – 43.50
Volume25.62K
Market Cap11.92M
P/E (TTM)0.00
Forward P/E0.00
EPS-1.91
Dividend Yield0.00%
Beta3.03
50-Day Avg4.21
200-Day Avg6.09

About

Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Lewis H. Bender M.A., M.B.A., M.S.
  • Employees5
  • Headquarters1 Enterprise Drive, Shelton, CT, United States, 06484-4779, USA
  • Websitehttps://intensitytherapeutics.com

Leadership

  • Mr. Lewis H. Bender M.A., M.B.A., M.S.Founder, President, CEO & Chairman of the Board · b. 1959
  • Mr. Joseph Talamo CPA, M.B.A.Chief Financial Officer · b. 1969
  • Mr. John Wesolowski CPA, M.B.A.Principal Accounting Officer & Controller · b. 1960
  • Mr. James M. AhlersExecutive Vice President of Corporate Finance · b. 1964

Financials

Income Statement

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue0000000
Cost of Revenue---179.04K147.00K25.00K26.00K
Gross Profit----179.04K-147.00K-25.00K-26.00K
Operating Expense---7.37M8.17M16.56M11.95M
Operating Income-5.68M-6.22M-8.01M-7.55M-8.32M-16.59M-11.97M
EBITDA-5.68M-6.22M-8.01M-7.32M-10.09M-16.27M-11.61M
Net Income-5.23M-5.96M-7.89M-7.58M-10.54M-16.27M-11.61M
R&D4.44M5.05M5.86M5.13M4.79M10.50M6.79M
Interest Expense--16.77K81.78K305.00K0-

Balance Sheet

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets9.01M10.15M5.22M1.76M17.30M4.78M14.10M
Total Liabilities1.31M11.71M13.90M16.86M4.13M1.86M2.23M
Total Equity7.70M-1.56M-8.68M-15.10M13.16M2.92M11.88M
Cash3.83M9.32M4.54M1.31M8.56M2.59M11.92M
Total Debt260.27K497.48K2.34M4.49M158.00K138.00K110.00K
Net Debt-3.57M-8.82M-2.20M3.18M-8.40M-2.45M-11.81M

Cash Flow

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-4.42M-5.37M-6.83M-5.48M-7.21M-15.22M-9.23M
Investing Cash Flow1.70M4.56M---6.02M6.35M-
Financing Cash Flow3.86M6.29M2.05M2.25M20.47M2.90M18.56M
Capital Expenditure0030000
Free Cash Flow-4.42M-5.37M-6.83M-5.48M-7.21M-15.22M-9.23M
Dividends Paid----1.32M--
FCF to OCF100.00%100.00%100.00%100.00%100.00%100.00%100.00%
Dividend Paid to FCF-----18.38%--

Earnings

Report DateSep 20, 2021Oct 28, 2021Jun 30, 2023Aug 14, 2023Nov 13, 2023Mar 14, 2024May 9, 2024Aug 8, 2024Nov 13, 2024Mar 13, 2025May 13, 2025Aug 7, 2025Nov 6, 2025Mar 12, 2026May 7, 2026Aug 11, 2026Nov 5, 2026
EPS Estimate0.000.00-0.39-10.00-2.25-0.18-0.34-8.00-7.62-0.22-3.25-0.16-1.50-0.05-1.09-0.81-0.94
EPS Actual-0.49-0.24-0.39-26.25-4.25-0.23-8.50-9.00-6.25-1.17-5.50-0.13-1.50-1.21-0.96-1.11-
Surprise--0.00%-162.50%-88.89%-28.56%-2400.00%-12.50%17.98%-431.82%-69.23%18.75%0.00%-2317.20%11.93%-37.04%-
Timing--After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours-After-hoursPre-market-

Key Statistics & Ratios

Market Cap11.92M
Enterprise Value3.81M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book1.42
EPS-1.91
Book Value3.13
Revenue (TTM)0
Gross Profit (TTM)0
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-195.88%
Return on Assets-89.91%
Shares Outstanding3.26M
Shares Float3.04M
Beta3.03
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 5 analystsTarget 19.33
  • Strong Buy
    1
  • Buy
    2
  • Hold
    2

Ownership Breakdown

Institutions
36.57%
Insiders
3.77%
Retail / Other
59.66%

Top Institutional Holders

  • KMT WEALTH MANAGEMENT, LLC
    496.49K15.21%
  • Sentinus, LLC
    26.72K0.82%
  • Geode Capital Management, LLC
    26.02K0.80%
  • NANO CAP NEW MILLENNIUM GROWTH FUND L P
    25.00K0.77%
  • Vanguard Capital Management, LLC
    16.84K0.52%
  • Mesirow Fin Investmt Mgmt Intl Equity
    14.12K0.43%
  • Vanguard Fiduciary Trust Co
    9.12K0.28%
  • Goss Wealth Management LLC
    1.15K0.04%
  • Wells Fargo & Co
    2000.01%
  • Advisor Group Holdings, Inc.
    2000.01%
  • UBS Group AG
    1920.01%
  • Tower Research Capital LLC
    670.00%
  • Mercer Global Advisors Inc.
    480.00%
  • Morgan Stanley - Brokerage Accounts
    200.00%
  • State Street Corp
    00.00%
  • Jane Street Group LLC
    00.00%
  • Warberg Asset Management LLC
    00.00%

Top Fund Holders

  • Fidelity Extended Market Index
    11.73K0.36%
  • Fidelity Series Total Market Index
    3.25K0.10%
  • Fidelity Total Market Index
    3.09K0.09%

Stock Splits

  • Feb 19, 20261:25